Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017
15% Year-Over-Year Growth, with Sales Set to More than Double by 2022
Epigenetic Drugs: Team Players in Combo Therapies
Scientists May Be Better Able to Destroy Tumors and Possibly Reverse CNS Decline
Bioelectricity, New Peer Reviewed Journal Announced
An Outstanding and Influential Foundation for a Dynamic, Emerging Field
Seeking New Users for iSeq
The Changing Sequencing Landscape
Andrea Toell Ph.D.
Andrea Toell, Ph.D., is a product manager at Lonza Walkersville. This article is, in part, a summary of the latest advancements in gene editing as discussed at the IBC’s Genome Editing Applications Meeting 2015, which was recently attended by Dr Toell.
More GEN Content From This Contributor
- Feature Articles: A CRISPR Look at Genome Editing
- Tutorials: Genome Editing: An Inside Job
- Feature Articles: Unlocking the Potential of CRISPR-Based Gene Editing